NEW YORK, Jan. 8, 2015 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds
investors that a securities class action has been filed in the
United States District Court for the Southern District of
New York on behalf of those who
purchased shares of Aeterna Zetaris Inc. ("Aeterna Zentaris" or the
"Company") (NasdaqCM:AEZS) shares during the period between
April 2, 2012 and November 6, 2014 (the "Class Period").
The Complaint charges Aetterna Zeratis and certain of its
executives with violations of federal securities laws. The
complaint alleges during the Class Period defendants misrepresented
or failed to disclose that: (1) the planned analysis of
macimorelin's pivotal clinical trial failed to meet its primary
efficacy endpoint pursuant to the Special Protocol Assessment
agreement letter between the Company and the FDA; (2) insufficient
data existed to confirm that the patients in the clinical trial
were accurately diagnosed with Adult Growth Hormone Deficiency; (3)
a serious cardiac event could have been attributed to macimorelin;
(4) as a result, the FDA would not approve the New Drug Application
for macimorelin in its present form; and (5), the Company's
statements about its business, operations and prospects, including
statements about macimorelin's prospects for FDA approval, were
materially false and misleading and/or lacked a reasonable
basis.
Plaintiff seeks to recover damages on behalf of all shareholders
who purchased shares of Aeterna Zentaris during the Class Period
described above.
No Class has yet been certified in the above action. If you wish
to review a copy of the Complaint, to discuss this action, or have
any questions, please contact Peretz
Bronstein, Esq. or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz
& Grossman, LLC at 212-697-6484 or via email info@bgandg.com.
Those who inquire by e-mail are encouraged to include their mailing
address and telephone number. If you suffered a loss in
Aeterna Zentaris you have until January 12,
2015 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn't
require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-reminds-investors-of-class-action-against-aeterna-zentaris-inc-and-lead-plaintiff-deadline-of-january-12-2015-300017512.html
SOURCE Bronstein, Gewirtz & Grossman, LLC